Status:
COMPLETED
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
Lead Sponsor:
Sebacia, Inc.
Conditions:
Acne Vulgaris
Eligibility:
All Genders
12-45 years
Phase:
NA
Brief Summary
Prospective, randomized, controlled, parallel group clinical study with blinded assessment evaluating Sebacia Microparticles (SM) with Nd:Yag laser in facial inflammatory acne vulgaris
Eligibility Criteria
Inclusion
- Mild to moderate acne vulgaris
- At least 15 inflammatory acne lesions
- Skin phototype I - III
- Able to understand and comply with study requirements
Exclusion
- Severe acne vulgaris
- Nodulocystic acne
- Ongoing use of medications and/or treatments for acne
- New hormone regimen (used for less than 12 weeks)
- Significant medical or mental health condition
Key Trial Info
Start Date :
September 25 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 10 2018
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT03303170
Start Date
September 25 2017
End Date
April 10 2018
Last Update
October 14 2019
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Clear Dermatology & Aesthetics Center
Scottsdale, Arizona, United States, 85255
2
Scripps Health
San Diego, California, United States, 92121
3
Miami Dermatology & Laser Institute
Miami, Florida, United States, 33173
4
Meridian Clinical Research
Savannah, Georgia, United States, 31406